A5061232025- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Head and Neck Cancer Studies
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Prostate Cancer Treatment and Research
- Ear and Head Tumors
- Boron Compounds in Chemistry
- Radiation Detection and Scintillator Technologies
- Sinusitis and nasal conditions
- Radiopharmaceutical Chemistry and Applications
- Cell death mechanisms and regulation
- Medical Imaging Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- DNA Repair Mechanisms
- Nuclear Physics and Applications
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Nanoplatforms for cancer theranostics
National Center for Oncological Hadrontherapy
2016-2025
Nanjing Medical University
2019
Ospedale SS. Annunziata
2019
Ankara Yıldırım Beyazıt University
2019
Jiangsu Cancer Hospital
2019
Azienda Ospedaliera Sant'Andrea
2016
Barts Health NHS Trust
2015
Ripamonti
2010
CRUK/MRC Oxford Institute for Radiation Oncology
2010
University of Milan
2010
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to facilitate repair. Inhibitors of PARP efficiently kill breast, ovarian, prostate tumors in patients carrying hereditary mutations the homologous recombination (HR) genes BRCA1 BRCA2 through synthetic lethality. Here, we surprisingly show that PARP1 hyperactivated replicating BRCA2-defective cells. hyperactivation explained defect HR as shRNA depletion RAD54, RAD52,...
The serine/threonine protein kinase aurora B, a key regulator of mitosis, is emerging as novel drug target for cancer treatment. Aurora B overexpression has been previously documented by immunohistochemistry in several types human tumors. We assessed expression series 160 non-small cell lung (NSCLC) samples (60% stage I, 21% II, 11% III, and 8% IV). In addition, we determined the survivin p16, two molecules also involved cycle control. was expressed selectively tumor cells compared with...
The aim of this study is to evaluate results in terms local control (LC), overall survival (OS), and toxicity profile better identify factors influencing clinical outcome skull base chordoma treated with proton therapy (PT) carbon ion radiotherapy (CIRT).We prospectively collected analyzed data 135 patients between November 2011 December 2018. Total prescription dose the PT group (70 patients) CIRT (65 was 74 Gy relative biological effectiveness (RBE) delivered 37 fractions 70.4 Gy(RBE) 16...
In particle therapy, the uncertainty of delivered range during patient irradiation limits optimization treatment planning. Therefore, an in vivo verification device is required, not only to improve plan robustness, but also detect significant interfractional morphological changes itself. this article, effective and robust analysis regions with a discrepancy proposed. This study relies on by means in-beam Positron Emission Tomography (PET) was carried out INSIDE system installed at National...
The growing interest in proton therapy (PT) recent decades is justified by the evidence that protons dose distribution allows maximal release at tumor depth followed sharp distal fall-off. But, holistic management of head and neck cancer (HNC), limiting potential PT to a mere dosimetric advantage appears reductive. Indeed, precise targeting may help evaluate effectiveness de-escalation strategies, especially for patients with human papillomavirus associated-oropharyngeal (OPC) nasopharyngeal...
Background and purpose: To present the clinical outcomes of two series patients treated with carbon-ion radiotherapy (CIRT) definitive photon (RT) for adenoid cystic carcinoma head neck (HN-ACC). Material methods: The first cohort six was referred from Oslo University Hospital (OUS) to Centro Nazionale di Adroterapia Oncologica (CNAO, Pavia, Italy) CIRT in 2014–2017. second included 18 RT at OUS 2005–2017. primary endpoint an evaluation osteoradionecrosis (ORN) cohorts. secondary endpoints...
(1) Background: we proposed an integrated strategy to support clinical allocation of nasopharyngeal patients between proton and photon radiotherapy. (2) Methods: intensity-modulated therapy (IMPT) plans were optimized for 50 consecutive carcinoma (NPC) treated with volumetric modulated arc (VMAT), differences in dose normal tissue complication probability (ΔNTCPx-p) 16 models calculated. Patient eligibility IMPT was assessed using a model-based selection (MBS) following the results 7/16...
Morphological changes that may arise through a treatment course are probably one of the most significant sources range uncertainty in proton therapy. Non-invasive in-vivo monitoring is useful to increase quality. The INSIDE in-beam Positron Emission Tomography (PET) scanner performs and carbon therapy treatments at National Center Oncological Hadrontherapy (CNAO). It currently clinical trial (ID: NCT03662373) has acquired PET data during various patients. In this work we analyze (IB-PET)...
Goal:In-beam Positron Emission Tomography (PET) is a technique for in-vivo non-invasive treatment monitoring proton therapy. To detect anatomical changes in patients with PET, various analysis methods exist, but their clinical interpretation problematic. The goal of this work to investigate whether the gamma-index analysis, widely used dose comparisons, an appropriate tool comparing in-beam PET distributions. Focusing on head-and-neck patient, we map and passing rate are sensitive...
The clinical application of different relative biological effectiveness (RBE) models for carbon ion RBE-weighted dose calculation hinders a global consensus in defining normal tissue constraints. This work aims to update the local effect model (LEM)-based constraints rectum using microdosimetric kinetic (mMKM)-defined values, relying on RBE translation and analysis long-term outcomes. LEM-optimized plans treated patients, having suffered from prostate adenocarcinoma (n = 22) sacral chordoma...
Abstract The high dose conformity and healthy tissue sparing achievable in Particle Therapy when using C ions calls for safety factors treatment planning, to prevent the tumor under-dosage related possible occurrence of inter-fractional morphological changes during a treatment. This limitation could be overcome by range monitor, still missing clinical routine, capable providing on-line feedback. Dose Profiler (DP) is detector developed within INnovative Solution In-beam Dosimetry...
Objective: To compare radiation-induced toxicity and dosimetry parameters in patients with locally advanced nasopharyngeal cancer (LANPC) treated a mixed-beam (MB) approach (IMRT followed by proton therapy boost) an historic cohort of full course IMRT-only.Material methods: Twenty-seven LANPC the MB were compared to similar 17 IMRT-only. The consisted first phase IMRT up 54–60 Gy second delivered boost 70–74 (RBE). total dose for IMRT-only was 69.96 Gy. Induction chemotherapy administrated...